22nd Century Group Inc (NASDAQ:XXII)
| 3.04 Delayed Data As of Sep 17 |  -0.06 / -1.94%Today’s Change | 0.56 Today|||52-Week Range 6.07 | +38.18% Year-to-Date |
Latest XXII News | Press Releases
| 22nd Century Group (Finally) Unveils Its Third Business Sep 15 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 3.10 |
| Today’s open | 3.10 |
| Day’s range | 3.03 - 3.15 |
| Volume | 61,994 |
| Average volume (3 months) | 2,321,761 |
| Market cap | $525.6M |
Data as of 4:00pm ET, 09/17/2021
Growth & Valuation
| Earnings growth (last year) | +32.94% |
| Earnings growth (this year) | -21.43% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +8.82% |
| P/E ratio | NM |
| Price/Sales | 10.86 |
| Price/Book | 10.18 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALDXAldeyra Therapeutics... | +0.02 | +0.23% |
| VSTMVerastem Inc | +0.07 | +2.59% |
| XBITXBiotech Inc | +0.31 | +1.98% |
| AUTLAutolus Therapeutics... | +0.11 | +1.67% |
Data as of 4:00pm ET, 09/17/2021
Financials
| Next reporting date | November 11, 2021 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $28.1M |
| Annual profit (last year) | -$19.7M |
| Net profit margin | -70.12% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Buffalo, New York |
Forecasts
